ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 2,160,000 shares, a growth of 5.4% from the October 15th total of 2,050,000 shares. Based on an average daily volume of 310,500 shares, the days-to-cover ratio is presently 7.0 days.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ANIP. SG Americas Securities LLC acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $106,000. Swiss National Bank raised its stake in shares of ANI Pharmaceuticals by 7.7% in the 1st quarter. Swiss National Bank now owns 32,300 shares of the specialty pharmaceutical company’s stock valued at $2,233,000 after acquiring an additional 2,300 shares during the period. Sei Investments Co. raised its stake in shares of ANI Pharmaceuticals by 16.4% in the 1st quarter. Sei Investments Co. now owns 11,321 shares of the specialty pharmaceutical company’s stock valued at $783,000 after acquiring an additional 1,594 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 2.9% in the 1st quarter. Russell Investments Group Ltd. now owns 106,675 shares of the specialty pharmaceutical company’s stock worth $7,374,000 after acquiring an additional 3,027 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of ANI Pharmaceuticals by 10.0% during the 1st quarter. ProShare Advisors LLC now owns 4,447 shares of the specialty pharmaceutical company’s stock worth $307,000 after purchasing an additional 404 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Down 4.0 %

Shares of NASDAQ ANIP opened at $56.58 on Friday. The stock has a market cap of $1.19 billion, a PE ratio of -102.87 and a beta of 0.71. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 12-month low of $48.20 and a 12-month high of $70.81. The company has a 50-day moving average of $58.40 and a 200 day moving average of $61.31.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter last year, the firm earned $1.05 earnings per share. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. As a group, sell-side analysts predict that ANI Pharmaceuticals will post 3.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the company. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Truist Financial boosted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. HC Wainwright restated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Raymond James lifted their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. Finally, Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $77.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.